Capital Advantage Inc. increased its stake in Amgen Inc. (NASDAQ:AMGN) by 0.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,136 shares of the medical research company’s stock after acquiring an additional 3 shares during the quarter. Capital Advantage Inc.’s holdings in Amgen were worth $368,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of the stock. Financial Advisory Service Inc. lifted its stake in shares of Amgen by 0.3% in the second quarter. Financial Advisory Service Inc. now owns 1,974 shares of the medical research company’s stock worth $340,000 after acquiring an additional 5 shares during the period. Capital Advisors Ltd. LLC lifted its stake in shares of Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,103 shares of the medical research company’s stock worth $190,000 after acquiring an additional 7 shares during the period. Ballentine Partners LLC lifted its stake in shares of Amgen by 0.3% in the second quarter. Ballentine Partners LLC now owns 3,441 shares of the medical research company’s stock worth $620,000 after acquiring an additional 9 shares during the period. Investment Partners Ltd. OH ADV lifted its stake in shares of Amgen by 0.5% in the second quarter. Investment Partners Ltd. OH ADV now owns 2,192 shares of the medical research company’s stock worth $377,000 after acquiring an additional 11 shares during the period. Finally, Conservest Capital Advisors Inc. lifted its stake in Amgen by 0.4% in the second quarter. Conservest Capital Advisors Inc. now owns 3,130 shares of the medical research company’s stock valued at $539,000 after buying an additional 13 shares during the period. 78.20% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This piece was reported by Markets Daily and is the property of of Markets Daily. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.themarketsdaily.com/2017/11/13/amgen-inc-amgn-position-boosted-by-capital-advantage-inc.html.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction on Monday, October 9th. The stock was sold at an average price of $185.95, for a total value of $283,573.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Carbonnel Francois De sold 4,000 shares of the company’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total value of $694,440.00. The disclosure for this sale can be found here. 0.19% of the stock is owned by corporate insiders.
Shares of Amgen Inc. (AMGN) opened at $172.35 on Monday. Amgen Inc. has a 1-year low of $138.83 and a 1-year high of $191.10. The stock has a market capitalization of $125,110.70, a price-to-earnings ratio of 13.70, a P/E/G ratio of 2.50 and a beta of 1.37. The company has a current ratio of 6.07, a quick ratio of 5.72 and a debt-to-equity ratio of 1.05.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.11 by $0.16. The firm had revenue of $5.77 billion during the quarter, compared to the consensus estimate of $5.75 billion. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The business’s revenue for the quarter was down .7% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.02 EPS. analysts forecast that Amgen Inc. will post 12.66 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Friday, November 17th will be paid a $1.15 dividend. The ex-dividend date of this dividend is Thursday, November 16th. This represents a $4.60 dividend on an annualized basis and a yield of 2.67%. Amgen’s dividend payout ratio (DPR) is presently 41.63%.
Amgen declared that its Board of Directors has initiated a share repurchase plan on Wednesday, October 25th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical research company to buy shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.
AMGN has been the topic of several recent analyst reports. BMO Capital Markets reissued a “market perform” rating and issued a $198.00 price target on shares of Amgen in a research note on Thursday, October 26th. Cann reissued a “buy” rating on shares of Amgen in a research note on Monday, August 28th. Oppenheimer Holdings, Inc. reissued a “buy” rating and issued a $203.00 price target on shares of Amgen in a research note on Thursday, September 7th. Mizuho reissued a “buy” rating and issued a $198.00 price target (up from $183.00) on shares of Amgen in a research note on Thursday, September 28th. Finally, Zacks Investment Research lowered Amgen from a “buy” rating to a “hold” rating in a research note on Monday, October 16th. Thirteen research analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. Amgen presently has a consensus rating of “Buy” and an average price target of $190.03.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.